Key facts
- This page summarizes Robert Lisicki's Form 4 filing for ARENA PHARMACEUTICALS INC.
- 4 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 05 Aug 2021, 18:08.
Robert Lisicki - 03 Aug 2021 Form 4 Insider Report for ARENA PHARMACEUTICALS INC
- Reporting relationship
- EVP, Chief Commercial Officer
- Issuer ticker
- N/A
- Reported as of
- 03 Aug 2021
- Net transaction value
- -$334,857
- SEC form
- 4
- Accepted by SEC
- 05 Aug 2021, 18:08:21 UTC
- Next SEC filing
- 05 Jan 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Andrew J. Cronauer, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Robert Lisicki filed Form 4 for ARENA PHARMACEUTICALS INC on 05 Aug 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: -$334,857.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ARNA
transaction
Common Stock
Options Exercise
- Transaction value
- $716,625
- Shares
- +17,500
- Change %
- +109%
- Price
- $40.95
- Shares after
- 33,601
- Date
- 03 Aug 2021
- Ownership
- Direct
- Footnotes
- F1
ARNA
transaction
Common Stock
Sale
- Transaction value
- $335,403
- Shares
- -5,605
- Change %
- -17%
- Price
- $59.84
- Shares after
- 27,996
- Date
- 03 Aug 2021
- Ownership
- Direct
- Footnotes
- F1, F2
ARNA
transaction
Common Stock
Sale
- Transaction value
- $716,079
- Shares
- -11,895
- Change %
- -42%
- Price
- $60.20
- Shares after
- 16,101
- Date
- 03 Aug 2021
- Ownership
- Direct
- Footnotes
- F1, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ARNA
transaction
Derivative
Employee Stock Option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -17,500
- Change %
- -14%
- Price
- $0.000000
- Shares after
- 110,000
- Date
- 03 Aug 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 17,500
- Exercise price
- $40.95
- Footnotes
- F1, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The transactions reported in this line item of this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.
Footnote F2
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.63 to $59.99, inclusive. The reporting person undertakes to provide Arena Pharmaceuticals, Inc., any security holder of Arena Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4.
Footnote F3
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.74, inclusive.
Footnote F4
The options vest over four years, with 25% of the shares subject to the option vesting on November 26, 2019, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested.